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A Systematic Review into the Incidence, Severity and Duration of 
Antidepressant Withdrawal Effects: Are Guidelines Evidence-Based?  
 
 
 
Abstract: 
 
Introduction 
 
The U.K.’s current National Institute for Health and Care Excellence and 
the American Psychiatric Association’s depression guidelines state that 
withdrawal reactions from antidepressants are ‘self-limiting’ (i.e. typically 
resolving between 1-2 weeks). This systematic review assesses that claim. 
 
Methods 
 
A systematic literature review was undertaken to ascertain the incidence, 
severity and duration of antidepressant withdrawal reactions. We identified 
23 relevant studies, with diverse methodologies and sample sizes.  
 
Results 
 
Withdrawal incidence rates from 14 studies ranged from 27% to 86% with a 
weighted average of 56%.  Four large studies of severity produced a 
weighted average of 46% of those experiencing antidepressant withdrawal 
effects endorsing the most extreme severity rating on offer. Seven of the ten 
very diverse studies providing data on duration contradict the UK and USA 
withdraw Guidelines in that they found a significant proportion of people 
who experience withdrawal do so for more than two weeks, and that it is not 
uncommon for people to experience withdrawal for several months. The 
findings of the only four studies calculating mean duration were, for quite 
heterogeneous populations, 5 days, 10 days, 43 days and 79 weeks.  
 
 
Conclusions 
 
We recommend that U.K. and U.S.A. guidelines on antidepressant 
withdrawal be urgently updated as they are clearly at variance with the 
evidence on the incidence, severity and duration of antidepressant 
withdrawal, and are probably leading to the widespread misdiagnosing of 
withdrawal, the consequent lengthening of antidepressant use, much 
unnecessary antidepressant prescribing and higher rates of antidepressant 
prescriptions overall. We also recommend that prescribers fully inform 
patients about the possibility of withdrawal effects. 
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1. Introduction  
Antidepressants (ADs) are one of the most commonly used drug classes in the U.K. 
and U.S., with prescriptions and duration of use rising each year. In the U.K. usage 
has risen since 2000 by 170%, with over seven million adults (16% of the English 
adult population) being prescribed an AD in England alone last year (2016-17) 
(DHSC, 2018), and with the number of individual annual prescriptions now topping 
65 million (NHS Digital, 2017). Additionally, round half of all AD users [approx. 3.5 
million people in England (8% of the population)] have been taking ADs for longer 
than two years, (Johnson et al., 2012). In the U.S. almost 8% of the population aged 
over 12 used ADs (in a given month) in 1999-2002, a figure rising to almost 13% (37 
million adults) by 2011-2014 (CDCP, 2017). Around one-half of AD users in the U.S. 
[approx. 18 million people (7% of the population)] have been taking them for at least 
5 years (Mojtabai & Olfson, 2014). Furthermore, the average duration of AD use has 
more than doubled since the mid-2000s in both the U.K. (NHS Digital 2017) and the 
U.S. (Mojtabai & Olfson, 2014). 
 
Previous research on long-term use has estimated that a third of people in the U.K. 
who take ADs for more than two years have no evidence-based clinical indications for 
continuing to take them (Cruickshank & MacGillivray, 2008). Similar levels of 
unnecessary long-term prescribing have also been found in other, non-U.K. settings 
(Ambresin et al., 2015, Eveleigh et al., 2014, 2015). If we apply the percentages of 
such non-indicated prescribing to today’s long-term use figures, we could estimate 
that approximately 1.2 million long-term AD users in England, and 6 million users in 
the U.S., could be taking ADs without clinical indication and could therefore try 
withdrawing.  
 
As a previous review indicates, antidepressants have been long known to induce 
withdrawal reactions in a large proportion of users (Haddad, 1997). While in some 
people such reactions may be mild, of short duration and manageable with 
reassurance and explanation (Haddad, 1997) in other people, even with slow 
withdrawal, these reactions are severe, long-lasting and can make normal functioning 
impossible (Anon, 1999). Typical AD withdrawal reactions include increased anxiety, 
flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, and 
hyperarousal. Dizziness, electric shock-like sensations, brain zaps, diarrhoea, 
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headaches, muscle spasms and tremors, agitation, hallucinations, confusion, malaise, 
sweating and irritability are also reported (Warner et al., 2006, Healy, 2014). 
Although the aforementioned symptoms are the most common physical symptoms, 
there is also evidence that AD withdrawal can induce mania and hypomania, (Naryan 
& Haddad, 2011, Goldstein, et al., 1999) emotional blunting and an inability to cry, 
(Holguin-Lew & Bell, 2013) long-term or even permanent sexual dysfunction (Csoka 
& Shipko, 2006).  
 
Current US clinical guidelines indicate that withdrawal reactions ‘typically resolve 
without specific treatment over 1–2 weeks’ (APA, 2010 p. 39), with current U.K 
guidelines similarly stating, that ‘[withdrawal] symptoms are usually mild and self-
limiting over about 1 week’ (NICE, 2009, 1.9.2.1 in CG90). 
 
The purpose of the current study, therefore, was to evaluate the accuracy and 
helpfulness of these guidelines by conducting a systematic review of the research 
literature on the incidence, duration and severity of AD withdrawal.  
 
 
2. Methods 
The inclusion criteria for the review were any research articles published in peer-
reviewed journals, in English, providing clear, comparable data about the incidence, 
duration or severity of withdrawal from ADs. No time restriction was employed in 
relation to when the studies were conducted. Studies were included regardless of 
diagnosis, as withdrawal effects are not influenced by the problem for which they are 
prescribed. Individual (n=1) case studies were noted but excluded from numerical 
summaries or estimates.  
 
A systematic search, informed by PRISMA guidelines (Moher, 2009), was undertaken 
by one of the two reviewers using MeSH (Medical Subjects Headings) in the 
MEDLINE/PubMed database. The search terms deployed were: Antidepressants OR 
Antidepressant Medications (39,626) AND Withdrawal Symptoms (3,671) OR 
Withdrawal Effects (296) OR Withdrawal Syndrome (2,583) OR Discontinuation 
Syndrome (146) OR Discontinuation Symptoms (129) OR Dependence (88,098) OR 
Addiction (46,785). This produced 312 papers. Reviewing the Abstracts of these 312 
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revealed that 20 met our inclusion criteria. The other reviewer independently searched 
PsycINFO, Google Scholar and published literature reviews but found no additional 
relevant papers. Searching the bibliographies of the 20 papers also produced no 
further studies. However, a 2015 review identified two additional relevant studies. An 
additional survey addressing duration and severity (in which one of the reviewers - JD 
- was involved), published in a recent report by the All-Party Parliamentary Group for 
Prescribed Drug Dependence in the UK, was also included in the review, bringing the 
total number of studies to 23. Seventeen pertained to incidence, four to severity and 
ten to duration (with eight addressing two of the three variables). 
 
 
3. Results 
3.1 Study Characteristics 
The methodologies of the 23 studies were heterogeneous and the sample sizes ranged 
from three to 1,367. Six of the 23 studies were drug-company funded and a further 
five involved researchers with conflicts of interest in relation to drug company money 
(see Tables 1-3). Four of the samples were in the UK, three each in Canada and the 
USA, two each in Italy and Japan and one each in Denmark, the Netherlands and New 
Zealand. The other six used international samples. Six were published in the 1990s, 
eight between 2000 and 2009, and nine since 2010, indicating a consistently low 
research interest in AD withdrawal.  
 
3.2 Incidence 
Our search revealed 17 studies providing data on incidence rates, 14 of which were 
deemed usable when calculating a weighted average (see Table 1). The 
methodologies were heteroegeneous. The most common approaches to assessing 
withdrawal were the Discontinuation-Emergent Signs and Symptoms (DESS) 
checklist, covering 43 symptoms (six studies, using from two to four symptoms as the 
cut off), and self-report based on self-definition of ‘withdrawal’ symptoms (three 
studies). Sample sizes ranged from 14 to 1,367. Eight provided data that compared 
AD drugs, which are recorded in Table 1, but not discussed further. Nine of the 17 
studies were either drug company funded (six) or involved authors with conflicts of 
interest from receipt of industry funds (three). 
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The largest three studies, all independent of drug-company influence, were online 
surveys. The first, by the Royal College of Psychiatrists (RCPsych) in the U.K. found 
that of 817 AD users, 512 (63%) experienced varying types and degrees of 
withdrawal reaction upon AD cessation (RCPsych, 2012). This is similar to the results 
derived from the largest direct-to-consumer survey of AD users to date. Of the 1,367 
New Zealand AD users in New Zealand who responded to a question about 
withdrawal, 55% replied that they had experienced some degree of withdrawal effects 
(Read et al., 2014). An international survey, utilising almost identical methodology as 
the New Zealand study, also found that 55% (of 953 AD users) reported withdrawal 
effects (Read &. Williams 2018).  In the New Zealand cohort the percentage reporting 
withdrawal effects rose to 74% among those who had been on the drugs for more than 
three years (Cartwright et al., 2016).  
 
These three studies had the largest sample sizes to date (and did not restrict the period 
during which withdrawal reactions were reported), but the samples were neither 
randomised nor stratified. It is therefore possible that they may have over-represented 
people who were dissatisfied with ADs. However, as the majority of the participants 
reported that the ADs had reduced their depression, in both the New Zealand (83%) 
and international (65%) studies the ‘dissatisfaction bias’ concern seems minimal. 
(Satisfaction data was not provided in the RCPsych study).  
 
Table 1 also summarises eleven other, smaller studies, with diverse methodologies, 
mostly using assessment periods of just 5 to 14 days. A multicentre study of 86 
people who had been on ADs for over three months, found that 66 (77%) exhibited 
withdrawal symptoms within seven days of having the drug abruptly replaced with 
placebo (Hindmarch et al., 2000).  An 8-week multicentre randomised trial 
comparing sertraline and venlafaxine XR in 163 patients with MDD, revealed 
withdrawal reactions in a combined average of 64% of users (Sir, et al., 2005). An 
RCT study of 95 people who abruptly stopped taking fluoxetine indicated 67% 
experienced withdrawal reactions, (Zajecka et al., 1998) and a case-report study of 
14 people who abruptly withdrew from fluvoxamine found that 86% experienced 
withdrawal (Black et al., 1993). An additional randomised clinical trial of SSRI 
withdrawal, covering 185 people, revealed an average withdrawal incidence of 46% 
(Rosenbaum et al. 1998). An additional study evaluating 25 outpatients treated with 
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escitalopram noted 14 (56%) experienced withdrawal reactions with higher dose and 
lower clearance leading to higher risk of withdrawal (Yasui-Furukori et al., 2016). A 
further study of 28 users of venlafaxine who were randomized to a three-day or 14-
day taper, indicated that 46% experienced withdrawal (Tint et al., 2008). Finally, a 
small study of 20 outpatients treated with SSRIs before slowly tapering off then found 
that 45% exhibited withdrawal reactions (45%) (Fava et al. 2007). 
 
Three studies report somewhat lower rates. One, an open trial of 95 people who 
discontinued their SSRIs, found 27% experienced withdrawal upon discontinuation 
(Bogetto et al., 2002). The second, a 12-week randomised, double-blind study of 
paroxetine patients, showed that of 55 withdrawing from paroxetine 35% developed 
withdrawal reactions upon abrupt discontinuation (Oehrberg et al. 1995). The third, a 
randomized, double-blind, placebo-controlled study of escitalopram, found that 27% 
of 181 people exhibited withdrawal reactions following abrupt replacement with 
placebo (Montgomery, Nil et al., 2005).   
 
These 14 methodologically diverse studies produced incidence rates ranging from 
27% to 86%, with a median of 55% and a weighted average of 56.4% (2991/5299). 
 
Excluded studies  
Incidence rates from a further three studies (all outliers, beyond the range of the 14 
studies above) were deemed unsuitable for inclusion in the calculation of the 
weighted average of incidence rates but are noted for completeness. The first was a 
retrospective study of the medical notes of 385 people who stopped paroxetine. It 
found that 11% of the patients’ notes recorded withdrawal (Himei & Okamura, 2006). 
As this study excluded any withdrawal commencing 3 days after discontinuation, and 
only assessed 9 withdrawal symptoms, lower rates may be an artefact of the study 
design. Furthermore it was a chart-review of medical notes, which relies on 
practitioners being aware of and recording withdrawal reactions. An earlier chart-
review, found a similar overall incidence of 12%, but suffered from similar 
methodological limitations (Coupland et al., 1996). A large study of people taking 
part in a withdrawal programme using tapering strips found that 97% had experienced 
withdrawal during previous attempts to stop ADs, but such a high rate is to be 
expected in this group, who are not representative of all AD users (Groot & Van Os, 
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2018). Had these three studies been included in the weighted average calculation the 
outcome (55.8% - 2260/4050) would have differed only slightly. 
 
In addition, two of the large surveys asked participants whether they had experienced 
addiction to the ADs. In the New Zealand survey (Read et al., 2014, 2018) 27% 
reported addiction (with 80% describing their addiction as ‘moderate’ or severe’). In 
the international survey 37% reported addiction (with 62% ‘moderate’ or ‘severe’ 
(Read & Williams, 2018). These findings, while important in their own right, were 
not included in the calculation of the weighted average as addiction and withdrawal 
are inter-related but different phenomena. 
 
Five other studies, all funded by drug companies, compared the average numbers of 
‘discontinuation symptoms’ resulting from the funder’s product and the competitors’ 
products, typically following artificially short treatment periods of eight to 12 weeks, 
and always using assessment periods of only five to 14 days (Baldwin et al., 2006; 
Judge et al., 2002; Michelson et al., 2000; Montgomery, Huusom et al. 2004; 
Montgomery, Kennedy et al., 2005). Because they also failed to report incidence rates 
in terms of percentages, these studies could not be included in Table 1. Nevertheless 
some of these studies produce further evidence that withdrawal reactions are 
common. For example one found that after just eight weeks on venlafaxine people 
experienced an average of five withdrawal symptoms when they stopped taking the 
drug (Montogmery, Huusom et al., 2004). 
 
3.3 Severity 
Our review discovered five studies reporting the severity of withdrawal effects. Four 
large, independently funded, studies found that nearly a half of people who have 
experienced withdrawal effects choose the most extreme option in the scale offered to 
them to describe the severity of those effects (see Table 2).  
 
All four studies involved surveys of AD use in the real world and therefore covered 
broad ranges of types of AD and duration of treatment. For example, the large New 
Zealand study covered a range of ADs (see (Table 1) and 52% had taken ADs for 
more than three years. This survey found that 46% of the 750 AD users who reported 
withdrawal effects ticked ‘severe’ and a further 32% ticked ‘moderate’, on a mild–
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moderate–severe scale. (Read et al., 2014). This was similar to the 43% (severe) and 
25% (moderate) findings for the 528 withdrawers in the large international sample, 
using the same scale (Read &. Williams, 2018). A recent Dutch study of people 
involved in a tapering programme found that of the 671 who had experienced 
withdrawal effects 339 (51%) reported the most extreme level of withdrawal; ‘very 
much’ (point 7 on a seven point sale of severity) (Groot & Van Os, 2018). In a recent 
international survey, 580 people who had attempted withdrawal from ADs responded 
to the question ‘how severely do you feel withdrawal has impacted upon your life’ On 
a scale of 0 -10). The mean response was 8.35 (SD = 2.05) denoting that the majority 
experienced severe reactions (median = 9, mode = 10), with 249 (43%) indicating the 
highest level of severity on the scale (10) (Davies et al. 2018).  
 
Thus, the percentages selecting the most extreme level of severity on offer in these 
four studies ranged from 43% to 51%, with a weighted average of 45.7% 
(1157/2529).  
 
Excluded study  
The fifth study was a drug company funded study comparing sertraline versus 
venlafaxine. After a two week taper, the withdrawal reactions of 110 patients were 
rated as ‘severe’ by two and as ‘very severe’ by one (Sir, et al., 2005). These low 
severity rates would have been minimised by the treatment period being artificially 
short (eight weeks), compared to the four surveys of the real life experiences of 
people on antidepressants for months or years. Furthermore, in the drug company 
study severity was clinician-rated rather than the self-report used in the other four 
studies. Including this outlier in the weighted average would have reduced it slightly, 
to 43.5% (1158/2664). 
 
3.4 Duration 
Regarding the duration of withdrawal reactions, we identified ten relevant studies (see 
Table 3). Three involved conflicts of interest but none were drug-company funded. 
 
One open trial study of 26 patients (treated for eight weeks or more) who experienced 
withdrawal effects when discontinuing under clinical supervision found that the 
effects lasted for an average of five days (Bogetto et al., 2002). Another small open 
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trial showed that three out of nine people (33%) experienced withdrawal for longer 
than a month, under the ‘slowest possible tapering’ (Fava et al., 2007). A study of 
spontaneous reports by UK doctors to a national data base found that 71 reported on 
duration of withdrawal effects. The effects lasted for between one and 52 days, with 
an average of 10.5 days. (Price et al., 1996). However, 34% of the 430 people who 
had had a withdrawal reaction when stopping paroxetine had reactions that were so 
severe and/or long-lasting that they had to be treated with a reintroduction of the drug, 
so the actual duration of untreated withdrawal reactions was minimised. 
 
The RCPsych survey of AD users found that for the 512 who experienced withdrawal 
the symptoms ‘generally lasted for up to 6 weeks’ and that  ‘A quarter of our group 
reported anxiety lasting more than 12 weeks’ (how much longer than 12 weeks was 
not reported) (RCPsych 2012). A recent international survey found that of the 580 
people who had experienced AD withdrawal and who answered the question ‘How 
long have you experienced withdrawal symptoms?’ 86.7% responded at least two 
months, 58.6% at least one year, and 16.2% more than three years (Davies et al. 
2018). 
 
Additionally, a recent content analysis of a population likely to have experienced 
withdrawal difficulties assessed the content of 137 online posts about AD withdrawal 
in the real world. The mean duration of withdrawal symptoms was 90.5 weeks for the 
97 SSRI users and 50.8 weeks for the 40 SNRI users (Stockmann et al., 2018).  
 
A randomised control trial of discontinuation from fluoxetine found that 40% of 58 
people who abruptly withdrew were still experiencing withdrawal symptoms at 6 
weeks after discontinuation, with no further follow up (Zajecka et al., 1998). In a 
study reviewing cases of ‘AD discontinuation manic states’, the eight for which 
duration of withdrawal reactions was known, produced a mean duration of 43 days - 
ranging from nine to 198 days (Narayan & Haddad, 2011). A review of three cases 
being treated for withdrawal with CBT, reported withdrawal duration of over three 
months for all cases (Belaise et al., 2014). A further case-report study assessed 46 
cases of SSRI discontinuation, with 26 containing information on duration symptoms. 
In 11 of these 26 cases (47.6%), symptoms resolved in less than 1 week, while in the 
rest of cases (52.4%), duration ranged from one to 13 weeks (Black et al., 2000). In 
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this study the withdrawal symptoms of an additional 17 people only ended after the 
reintroduction of an AD, meaning that only 26% (11/43) experienced spontaneous 
remission of their withdrawal symptoms within one week.  
The ten studies do not permit a weighted average, because of the variety of 
methodologies and ways duration was reported. Seven out of the ten studies 
contradict the UK and USA withdraw Guidelines in that they found that a significant 
proportion of people experiencing withdrawal do so for more than two weeks (Belaise 
et al., 2014; Davies et al., 2018; Fava et al., 2007; Narayan & Haddad, 2010; 
Stockman et al., 2018; RCPsych 2012; Zajecka et al., 1998).  
For example, one study found withdrawal lasting at least six weeks in 40% of people 
Zajecka et al., 1998) and another found it lasting at least 12 weeks in 25% (RCPsych, 
2012). Many examples of longer durations, beyond a year, are reported by two recent, 
real life samples of people experiencing difficulties with withdrawal (Davies & Pauli, 
2018; Stockman et al., 2018).  
 
4. Discussion 
Our review of the quantitative studies concludes that more than half (56%) of AD 
users experience withdrawal, with the majority of these describing their withdrawal as 
moderate or severe, and nearly half (46%) as severe. Seven of the ten very diverse 
studies providing data on duration contradict the UK and USA withdraw Guidelines 
in that they found a significant proportion of people who experience withdrawal do so 
for more than two weeks, and that it is not uncommon for people to experience 
withdrawal for several months and beyond. 
 
Furthermore, two of the studies reviewed indicate that for 40% of people who 
withdraw the effects last at least 6 weeks (Zajecka et al., 1998) and for 25% they last 
12 weeks or more (RCPsych, 2012). Given that around 7 million individuals were 
prescribed ADs in England last year and around 37 million in the U.S., it is possible 
that around 2.8 million people in England and 14.8 million in the U.S. (about 5% of 
the U.S. and English populations) may experience AD withdrawal for at least six 
weeks after cessation, and 1.8 million and 9 million respectively may experience 
withdrawal for at least 12 weeks. 
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These findings differ significantly from those implied in both the U.K. (NICE, 2009) 
and U.S. guidelines (APA, 2010) on AD withdrawal. Furthermore, these findings are 
not alone in contradicting current guidelines. For instance, a 2015 review of 
quantitative studies and 38 case reports, noted that in only 4 out of 18 case reports 
(22%) did withdrawal symptoms spontaneously remit within 2 weeks, and in two 
cases paroxetine withdrawal was present up to one year after discontinuation. It 
concluded that while withdrawal reactions ‘typically occur within a few days from 
drug discontinuation and last a few weeks…. many variations are possible, including 
late onset and/or longer persistence of disturbances’ (Fava et al., 2015). 
4.1 ‘Discontinuation Syndrome’ vs.‘Withdrawal’ 
Given that AD withdrawal is of higher incidence, severity and longer duration than 
current guidelines acknowledge, a number of key implications follow. Firstly, using 
the term ‘discontinuation syndrome’ to characterise AD withdrawal runs contrary to 
the evidence. While ‘discontinuation syndrome’ has been used sporadically in the 
literature since the 1960s, its established meaning with respect to ADs was first 
operationally defined at the ‘Discontinuation Consensus Panel’ funded by Eli Lilly in 
1996 (Schatzberg, 1997, Schatzberg et al., 1997), where it was delineated as a ‘self-
limiting syndrome’ (e.g. comprising mild, transient and/or more distressing symptoms 
that can lead to impairments in functioning or productivity), ‘typically resolving 
within 2 to 3 weeks’ (Rivas-Vazquez et al., 1999) and to be distinguished from other 
contentious withdrawal forms such as those generated by benzodiazepines and 
sedative hypnotics (Fava et al., 2015). 
 
The panel’s characterisation of withdrawal as ‘self-limiting’ and resolving within 2-3 
weeks (a position still broadly reflected in current guidelines), however, appears 
unsupported not only by the evidence the panel cited to substantiate the ‘self-limiting’ 
claim, (ADH 1996) but by subsequent evidence on duration (such as that covered by 
this review).  Furthermore, defining ‘withdrawal syndromes’ as those pertaining to 
benzodiazepines and antipsychotics, and ‘discontinuation syndromes’ to SSRIs, not 
only erroneously separates AD withdrawal from other CNS drug withdrawals but also 
minimises the vulnerabilities induced by SSRIs (Nielsen et al., 2012). The term 
‘discontinuation syndrome’ may further mislead as AD withdrawal can occur without 
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discontinuation (e.g. between two doses of rapid-onset and short-acting drugs and 
with a decrease in medication) (Fava et al., 2015), while the term ‘syndrome’ subtly 
medicalises withdrawal by associating it with a disorder endogenous to the person 
than with a non-dysfunctional reaction to the cessation of a drug. For these reasons, 
this review supports Fava et al., (2015) in stating that ‘discontinuation syndrome’ 
should be replaced with a term more consistent with the evidence, such as 
‘withdrawal’ or ‘withdrawal reaction’. 
 
4.2 Misdiagnosis of Withdrawal 
Another implication of AD withdrawal being of higher incidence and longer duration 
than current guidelines acknowledge, is that added credence is given to concerns that 
many doctors are misdiagnosing withdrawal – e.g. as relapse or treatment failure. One 
prevailing view deployed to counter this concern, is that misdiagnosis can be avoided, 
as it is possible to distinguish withdrawal reactions from relapse on the grounds that 
withdrawal usually commences within a few days after cessation and resolves quickly 
if the drug is reinstated, whereas relapse is uncommon in the first weeks after 
stopping treatment (Anon, 1999). This view is problematic, however, as many 
withdrawal variations are possible, including late onset of withdrawal and/or longer 
persistence of disturbances, meaning withdrawal symptoms may be easily 
misidentified as signs of impending relapse (Fava et al., 2015). For example, for drugs 
like fluoxetine, with a longer half-life, it is possible that withdrawal may commence 
many days or even weeks after cessation, confounding beliefs about withdrawal’s 
close proximity to cessation (Renoir, 2013). Furthermore, differing metabolic rates 
can also confound accurate predictions about the onset of withdrawal. Additionally, 
and crucially, re-emergent symptoms of depression and anxiety are a regular feature 
of AD withdrawal itself (Rosenbaum et al., 1998) - the RCPsych’s own survey found 
that the withdrawal reaction rated severe by most people was increased anxiety, with 
approximately 25% of users experiencing anxiety for at least 3 months after stopping 
their AD (RCPsych 2012). As ADs are now widely prescribed for anxiety-related 
problems, and as increased anxiety is a common withdrawal reaction, ignorance of 
withdrawal reactions could have led, in the past, to relapse being overestimated when 
ADs were withdrawn (Anon, 1999) and could still be leading, in the present, to 
genuine withdrawal being misread as relapse with drugs being reinstated and a more 
negative prognosis being issued. 
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Withdrawal can also be misdiagnosed in other ways: as failure to respond to treatment 
(e.g. where covert non-adherence is mistaken as the condition worsening, leading to 
dose increase or drug switching); or as bipolar I or II (e.g. where ‘manic’ of 
‘hypomanic’ withdrawal reactions are misdiagnosed as the early onset of bipolar); or 
as the result of switching medications  (e.g. where withdrawal reactions are 
misdiagnosed as side-effects of the new antidepressant) (Haddad & Anderson, 2007). 
 
Misdiagnosing AD withdrawal in the aforementioned ways would predict rising long-
term AD use, as many users, having their withdrawal experiences misread, would 
have their drugs reinstated and/or switched (and/or their dosage increased). Such 
rising long-term use is precisely what we find in the clinical population, with the 
average duration of AD use more than doubling since the mid-2000s in both the U.K. 
(NHS Digital, 2017) and the U.S. (Mojtabai & Olfson, 2014). 
 
4.3 Consistency with Qualitative Studies on Withdrawal  
Qualitative studies, where AD users are either asked open questions survey 
interviews, or have their spontaneous internet postings published, are also consistent 
with the findings of the current review. These studies also serve to bring those 
findings to life. Illustrative examples of personal testimony regarding the severity of 
withdrawal effects follow: 
 
I am currently trying to wean myself off of Venlafaxine, which honestly is the 
most awful thing I have ever done. I have horrible dizzy spells and nausea 
whenever I lower my dose. (Pestello & Davis-Berman, 2008) 
 
I forgot to take my Citalopram for two days and woke up one morning with severe 
dizziness. It was so extreme that I fell over when I tried to get out of bed and I 
threw up. (Read et al., 2018) 
 
The withdrawal effects if I forget to take my pill are severe shakes, suicidal 
thoughts, a feeling of too much caffeine in my brain, electric shocks, 
hallucinations, insane mood swings. ….. kinda stuck on them now coz I’m too 
scared to come off it. (Gibson et al., 2016) 
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While there is no doubt I am better on this medication, the adverse effects have 
been devastating – when I have tried to withdraw - with “head zaps”, agitation, 
insomnia and mood changes. This means that I do not have the option of managing 
the depression any other way because I have a problem coming off this medication. 
(Cartwright et al., 2016). 
 
Testimonies relevant to the duration of the effects include: 
 
It took me 2 months of hell to come off the antidepressants. Was massively harder 
than I expected. (Read et al., 2018) 
 
It took me almost two years to get off Paroxetine and the side effects were 
horrendous. I even had to quit my job because I felt sick all the time. Even now 
that I am off of it, I still feel electric shocks in my brain (Pestello & Davis-Berman, 
2008) 
 
The difficulty of getting off has been a tough road and taken me years of trying and 
is something that doctors could be more knowledgeable of and supportive with. 
(Cartwright et al., 2016) 
 
4.4. Clinical Guidelines on Antidepressant Withdrawal 
A final implication of the incidence, severity and duration of AD withdrawal being 
higher than guidelines acknowledge, is that current guidelines are misleading doctors 
on the nature and management of withdrawal. As current U.K. (NICE, 2009) and U.S. 
(APA, 2010) depression guidelines are at variance with the conclusions of this 
research, a Freedom of Information Request was issued to NICE to ascertain the 
evidence base for its current statement on withdrawal – namely, that "[withdrawal] 
symptoms are usually mild and self-limiting over about 1 week" (NICE, 2009, 1.9.2.1 
in CG90). NICE responded that its current statement on AD withdrawal was inherited 
from an earlier statement issued in the previous 2004 guidelines, which stated that  
 
There are no systematic randomised studies in this area…. If symptoms are 
mild, reassure the patient that these symptoms are not uncommon after 
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discontinuing an antidepressant and that they will pass in a few days. (NICE, 
2004, 4.5.2.48 in CG23 italics added).  
 
NICE confirmed that evidence for both the above claims ‘has not been updated’ since 
2004. Furthermore, this evidence was derived, at the time, from only two pieces of 
research (e.g. Lejoyeux & Adès, 1997, Haddad 2001), neither of which, upon 
analysis, cites a single source that supports NICE’s later (2009) one-week claim.  
 
NICE’s current position on AD withdrawal was not only originally advanced on weak 
evidence, but is 14 years out of date and countered by subsequent evidence, as can be 
seen in this review. This raises concerns for the substantial number of AD users who 
will experience withdrawal for a longer duration than guidelines recognise. Assuming 
doctors honour such guidelines, many of these people will likely have their AD 
withdrawal misdiagnosed – e.g., as relapse or as a failure to respond to treatment - 
with ADs either being reinstated, switched or doses increased as a consequence. 
These practices, if routinely enacted, would help partly explain lengthening AD use, 
which has increased the number of AD prescriptions.  
 
That doctors are being misled by guidelines also legitimates concerns raised by 
affected people that their withdrawal was not properly acknowledged, understood and 
managed by doctors, something widely reported in survey data (Davies et al., 2018, 
Cartwright, 2016). This is also confirmed by the two largest surveys to date, which 
revealed that fewer than 2% of AD users recall being told anything by the prescriber 
about withdrawal effects, dependence or potential difficulties (Read et al., 2018; Read 
& Williams, 2018). Illustrative personal testimonies include: 
 
I was never fully informed of all side effects, short or long-term. …. If I had been 
more fully informed I would not have taken the medication for a long time or at 
all. 
 
I was never informed by doctors of long-term side effects or 
addiction/development of tolerance and went through extremely severe 
withdrawal symptoms attempting to get off. (Cartwright, et al. 2016). 
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5. Limitations 
The calculation of our estimates has not factored in differences between AD types, 
(e.g. differing half-lives affect timing of withdrawal onset) although table 1 shows 
that a broad range of SSRI’s are represented in the reviewed studies. Limitations have 
also been imported from the confines of the studies included, which regularly cover 
treatment of only short duration – 6 weeks (Tint et al., 2008) 8 weeks (Bogetto 2002, 
Sir, et al. 2005) 12 weeks (Zajecka 1998), to a median of 12 weeks (Narayan & 
Haddad 2011) - while undertaking limited follow up: at 3 days (Himei, T., Okamura, 
2006), at 14 days (Black 1998) at 4 weeks (Bogetto 2002) at six weeks (Zajecka 
1998) and at 12 weeks (RCPsych 2010). As short-term treatment will limit the 
occurrence of withdrawal upon discontinuation (Eveleigh et al., 2017), and as 
restricted follow-up will inevitably exclude post-follow-up withdrawal reactions, such 
delimitations will have probably led to the underestimation of both the incidence and 
duration of withdrawal in the studies reviewed, thus rendering our overall estimates 
conservative.  
 
Future research must determine the extent to which the misdiagnosis of withdrawal 
(leading to ADs being either reinstated or switched) has driven lengthening AD use 
since the mid-2000s. While shorter AD usage is associated with more successful AD 
discontinuation, (Eveleigh et al., 2017) rising long-term AD use is of serious concern. 
In addition to the obvious economic costs incurred, the human costs of long-term use 
are well documented, being linked with serious adverse effects such as increased 
severe side-effects, (Ferguson, 2001) the impairment of patients’ autonomy and 
resilience (increasing their dependence on medical help) (Kendrick, 2015), increased 
weight gain, (Gafoor et al., 2018) worsening outcomes for some patients, 
(Hengartner, et al., 2018, Shea, 1992) poorer long-term outcomes for major 
depressive disorder, (Vittengl, 2017) greater relapse rates, (Viguera, 1998) increased 
mortality (Maslej et al., 2017) and an increased risk of developing neurodegenerative 
disease, such as dementia (Richardson et al., 2018). It will also be important, 
therefore, to determine what people are told about withdrawal pre-treatment, to 
establish how regularly and accurately they are being forewarned of likely withdrawal 
reactions; warnings that will impact decision-making around accepting AD treatment.  
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Finally, given that the evidence reported here on AD withdrawal severity, incidence 
and duration differs from what guidelines state, future research must readdress the 
dependency-forming nature of ADs. This is particularly important as recent surveys 
reveal many AD users report being ‘addicted’ to ADs; for example. 37% from a 
sample of 943 (Read & Williams, 2018) and 27% from a sample of 1521 (Read et al., 
2004). Among 493 AD users 57% agreed with the statement ‘When you have taken 
antidepressants over a long period of time it is difficult to stop taking them’ and 56% 
agreed with ‘Your body can become addicted to antidepressants’ (Kessing et al. 
2005). As withdrawal is a central criterion for dependency, underestimates of 
withdrawal may well have impacted on past assessments of the extent to which ADs 
are dependency-forming. 
 
 
6. Conclusion 
The available research indicates that antidepressant withdrawal reactions are 
widespread, with incidence rates ranging from 27% to 86% (weighted average of 
56%), and with nearly half (46%) of those experiencing withdrawal describing these 
reactions as severe. Available research also indicates that current clinical guidelines in 
the U.K. and U.S are in urgent need of correction, in order to be evidence-based, as 
withdrawal effects are neither mostly ‘mild’ nor ‘self-limiting’ (i.e. typically 
resolving over 1-2 weeks), but are regularly experienced far beyond what current 
guidelines acknowledge.  
 
We therefore recommend that both sets of guidelines be urgently updated to reflect 
the evidence base on AD withdrawal.   
 
As a secondary recommendation we suggest that consideration be given to 
independent reviews of the processes by which the two bodies concerned construct 
clinical guidance around mental health interventions (e.g. how are panel members 
selected, by what criteria, and how is the quality of literature reviews assured). We 
also suggest that panel members are independent from the pharmaceutical industry, 
and that panels include experts-by-experience (ie AD users) and non-medical mental 
health professionals.  
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As the lengthening duration of AD use has fuelled rising AD prescriptions over the 
same time period, we must understand the drivers of such lengthening use. The 
evidence set out suggests that lengthening use may be partly rooted in the 
underestimation of the incidence, severity and duration of AD withdrawal reactions, 
leading to many withdrawal reactions being misdiagnosed, for example, as relapse 
(with drugs being reinstated as a consequence) or as failure to respond to treatment 
(with either new drugs being tried and/or dosages increased). This issue is pressing as 
long-term AD use is associated with increased severe side-effects, increased risk of 
weight gain, the impairment of patients’ autonomy and resilience (increasing their 
dependence on medical help), worsening outcomes for some patients, greater relapse 
rates, increased mortality and the development of neurodegenerative diseases, such as 
dementia.  
 
It is of serious concern that prescribed antidepressant medications are causing 
withdrawal effects that are often long-lasting and severe, and that this is not being 
recognised by current clinical guidelines and, by extension, prescribers. It is of 
additional concern that such poor recognition of AD withdrawal might be increasing 
the duration of AD use and, therefore, overall rates of antidepressant prescriptions.  
 
 
 
 
Declarations of interest: none 
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Table 1. Incidence of antidepressant withdrawal reactions  
 
STUDY 
and funding* 
 
AD type 
Treatment 
duration 
Abrupt/ 
Tapered 
Withdrawal 
assessment 
period 
Withdrawal 
incidence 
Montgomery, 
Nil  et al 2005  
DC 
escitalopram 
 
12 weeks  abrupt 2 weeks  27% (49/181) 1 
Bogetto et al 
2002 
IND 
paroxetine 
fluoxetine  
>  8 weeks mixed  
(67% 
tapered) 
4 weeks  27% (26/95) 2 
 
parox 42% (22/52) 
fluox   9% (4/45) 
Oehberg et al 
1995  
 DC 
paroxetine 12 weeks  abrupt 2 weeks 35% (19/55) 3 
Fava et al 2007 
IND 
fluoxetine 
fluvoxamine 
paroxetine 
citalopram   
sertraline 
?̅? = 29 
months 
> 6 months 
tapered 
(‘slowest 
possible’) 
1 year 45% (9/20) 1 
Tint et al 2008  
CI 
paroxetine 
fluoxetine 
venlafaxine  
citalopram  
fluvoxamine 
>  6 weeks tapered 
(‘brief’) 
5-7 days 46% (13/28) 4 
 
parox 56% (5/9) 
others 36% (4/11) 
Rosenbaum et al 
1998 
DC 
fluoxetine 
sertraline 
paroxetine 
 
?̅? = 11 
months 
abrupt 5-8 days 46% (86/185) 1 
 
sertr   60% (38/63) 
parox 66% (39/59) 
fluox 14% (9/63) 
Read et al 2014, 
2018 
IND 
paroxetine 
venlafaxine 
citalopram. 
fluoxetine  
sertraline 
escitalopram  
Tricyclics 
 
median 
(52%)  = > 3 
years 
mixed indefinite  
(online survey) 
55% (750/1367) 5 
 
parox 76% (82/108)  
venla 70% (19/27) 
Tricyc 51% (28/55) 
cital  47% (115/247)  
fluox 36% (97/273) 
escit  33% (5/15) 
sertr  18% (2/11) 
Read & 
Williams 2018 
IND 
sertraline 
fluoxetine 
citalopram 
venlafaxine 
paroxetine  
escitalopram  
duloxetine 
fluvoxamine  
Tricyclics 
 
median 
(62%) = > 3 
years 
mixed indefinite  
(online survey) 
55% (528/953) 5 
 
parox 69% (46/67) 
Tricyc 63% (37/59) 
fluox 62% (75/120) 
venla 60% (48/80) 
escit  56% (35/63) 
cital  55% (65/118) 
sertr  50% (61/121) 
fluvo 47% (7/15) 
dulox 31% (5/16) 
Yasui-Furukori escitalopram > 6 months tapered indefinite 56% (14/25) 6 
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et al 2016  
CI 
(every clinic 
visit) 
 
R.C.P. 2012 
? 
citalopram. 
fluoxetine  
venlafaxine  
sertraline 
escitalopram 
mirtazapine  
paroxetine 
duloxetine 
Tricyclics 
unknown – 
real-life 
mixed indefinite  
(online survey) 
63% (512/817) 5 
 
venla 82% (89/109) 
escit  75% (38/51) 
parox 69% (20/29) 
dulox 69% (18/26) 
sertra  62% (55/89) 
cital   60% (141/235) 
Tricyc 53% (23/43)  
fluox  44% (76/173) 
mirta  21%  (8/38) 
Zajecka et al 
1998  
CI 
fluoxetine 12 weeks abrupt 6 weeks 67% (64/95) 7 
Hindmarch et al 
2000 
DC 
fluoxetine 
sertraline  
paroxetine 
citalopram 
> 3 months abrupt  4-7 days 77% (66/86) 1  
 
parox 100% (22/22) 
fluox  77%  (17/22) 
cital 70%   (14/20) 
sertr 59%   (13/22) 
Sir et al 2005   
DC 
sertraline 
venlafaxine 
8 weeks tapered 13 2 weeks 85% (110/129) 8 
 
sertr  58% (39/67) 
venla 71% (44 /62) 
Black et al 1993 
DC 
fluvoxamine 8 months abrupt 2 weeks 86% (12/14) 9 
     
    WEIGHTED  
 
AVERAGE 
    
56.4% (2991/5299) 
 
* DC = study funded by drug company; CI = author(s) in receipt of drug company 
funding, or drug company employee; IND = independent; ? = unknown - no conflict 
of interest statement 
1 = > 4 of the 43 symptoms in Discontinuation-Emergent Signs and Symptoms 
(DESS) checklist  
2 =  > 2 DESS symptoms 
3= observation or spontaneous self report of any adverse event (i.e. not specifically 
asked about withdrawal symptoms or administered DESS) 
4 = > 3 DESS symptoms 
5= self defined 
6 = > 3 of a reduced DESS symptom list (25/43) 
7 = > 1 ‘new or worsened adverse event’ 
8 = AntiDepressant Discontinuation Scale (ADDS)  
9= any new symptom 
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Table 2. Severity of withdrawal effects 
 
STUDY 
and funding* 
Treatment 
duration 
 
Type of scale 
Percentage choosing most 
extreme level of severity 
Groot & van Os 2018      
IND 
unknown 0 - 7  51% (339/671) 
Read et al. 2014 
IND 
mode (52%)  
= > 3 years 
none/mild/ 
moderate/severe 
46% (342/750) 
Read & Williams 2018     
IND 
mode (62%) 
= > 3 years 
none/mild/ 
moderate/severe 
43% (227/528) 
Davies et al 2018    
IND 
unknown 0 - 10   43% (249/605) 
    
             WEIGHTED  AVERAGE  45.7% (1157/2529) 
 
 *  IND = independent 
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Table 3. Duration of withdrawal effects 
 
STUDY and 
funding* 
AD Type Treatment 
duration 
Abrupt/ 
Tapered 
Withdrawal 
assessment 
period 
 
N 
Duration 
Bogetto et al 
2002 1 
IND 
paroxetine  
fluoxetine  
>  8 weeks mixed 4 weeks 26 ?̅? = 5 days 
(range 1 - 10 
days) 
Price et al 
1996 2 
IND 
paroxetine unknown – 
real-life 
unknown – 
real-life 
indefinite  71 ?̅? = 10 days 
46%  < 1 week 
41%  8-14 days 
13%  > 2 weeks 
Black et al 
2000 3 
? 
paroxetine 
fluoxetine 
fluvoxamine 
sertraline 
> 1 month mixed indefinite 26 42%   < 1 week 
58%  1-13 weeks 
Fava et al 
2007 4 
IND 
SSRIs  ?̅? = 29 months 
> 6 months 
 
‘slowest 
possible 
tapering’ 
1 year 9 67%  < 1 month 
33%  > 1 month 
R.C.P. 2012 5 
? 
multiple 
(see Table 1)  
unknown – 
real-life 
mixed indefinite 
 
512  ‘generally up to 6 
weeks’ 
25% > 12 weeks  
Zajecka et al 
1998 6 
CI 
fluoxetine 12 weeks abrupt 6 weeks 75, 
58 
35% (26/75) in 
week 4 
40%  (23/58) in 
week 6 
Narayan & 
Haddad 2010 3 
CI 
TCAs, 
SSRIs, 
MAOIs, 
SNRIs 
>  4 weeks 
median = 3 
months 
mixed indefinite  8 ?̅? = 43 days) 
(range 9 - 198 
days) 
Belaise et al 
2014 3 
CI 
paroxetine > 4 years various indefinite 3 100% > 3 months 
Davies et al 
2018 5 
IND 
TCAs, 
SSRIs, 
MAOIs, 
SNRIs 
unknown – 
real-life 
unknown – 
real-life  
 
indefinite 605 87%  > 2 months 
59%  > 1 year 
16%  > 3 years  
Stockman et al 
2018 5 
IND 
SSRIs 
SNRIs 
?̅? = 5 years tapered 
 
indefinite 137 ?̅? = 79 weeks  
SSRIs ?̅? = 90 
weeks 
SNRIs ?̅? = 51 
weeks 
 
1 =  > 2 of the 43 symptoms in Discontinuation-Emergent Signs and Symptoms 
(DESS) checklist  
2 = spontaneous reports to national data base 
3 = case studies 
4 = > 4 DESS symptoms 
5 = self-report 
6 = = > 1 ‘new or worsened adverse event’ 
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